Susan Mahony Sells 36,585 Shares of Eli Lilly and Company (LLY) Stock

Eli Lilly and Company (NYSE:LLY) SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Eli Lilly and Company (NYSE:LLY) opened at $85.32 on Thursday. The stock has a market capitalization of $94,231.72, a PE ratio of 20.92, a price-to-earnings-growth ratio of 1.88 and a beta of 0.35. Eli Lilly and Company has a twelve month low of $66.39 and a twelve month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the company posted $0.88 earnings per share. The business’s revenue was up 9.0% on a year-over-year basis. sell-side analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

LLY has been the topic of a number of analyst reports. BMO Capital Markets restated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Wednesday, August 16th. BidaskClub lowered Eli Lilly and from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Leerink Swann reaffirmed a “hold” rating on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $90.25.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC purchased a new position in shares of Eli Lilly and during the third quarter worth about $916,000. Public Employees Retirement System of Ohio grew its holdings in shares of Eli Lilly and by 0.4% during the third quarter. Public Employees Retirement System of Ohio now owns 684,533 shares of the company’s stock worth $58,555,000 after buying an additional 2,452 shares during the last quarter. Garde Capital Inc. purchased a new position in shares of Eli Lilly and during the third quarter worth about $202,000. Archford Capital Strategies LLC grew its holdings in shares of Eli Lilly and by 26.2% during the third quarter. Archford Capital Strategies LLC now owns 8,076 shares of the company’s stock worth $690,000 after buying an additional 1,676 shares during the last quarter. Finally, Salem Investment Counselors Inc. lifted its position in Eli Lilly and by 7.5% in the third quarter. Salem Investment Counselors Inc. now owns 48,460 shares of the company’s stock valued at $4,173,000 after purchasing an additional 3,400 shares during the period. 76.43% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3078863/susan-mahony-sells-36585-shares-of-eli-lilly-and-company-lly-stock.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.